Myelofibrosis, a rare chronic myeloproliferative neoplasm disorder, is often an overlooked disease due to its rarity and underappreciation of the severity of clinical manifestations and burden of disease. This has led to multiple gaps in knowledge and understanding of the management of patients with myelofibrosis, especially the more severe or higher-risk forms. Drs. Aaron Gerds and Michael Grunwald discuss the current challenges that exist across the myelofibrosis landscape, including burden of disease, molecular abnormalities, pharmacologic options, and emerging novel therapies. Case studies are discussed to facilitate integration of key concepts into clinical practice.
Course Credit:
1 ACPE Contact Hour
1 AMA PRA Category 1 CreditTM
1 ANCC Contact Hour
1 CA-BRN Contact Hour
0.5 Pharmacology Hours
Dates:
Opens: 2023-04-30
Closes: 2024-04-30
Target Audience:
Hematologists, hematologist-oncologists, hematology advanced practitioners, hematology nurses, pharmacists, and other clinicians who diagnose or treat patients with myelofibrosis.
This educational activity is supported by an educational grant from GSK.
Accreditation
The Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Annenberg Center for Health Sciences at Eisenhower designates this knowledge-based activity for a maximum of 1 hour . Credit will be provided to NABP CPE Monitor within 60 days after the activity completion.
Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 1 contact hour, including 0.5 pharmacology hours.
To receive credit for education contact hours outside of the state of California, please check with your state board of registered nursing for reciprocity.
Additional Content Planners
Christopher Elder, PharmD, BCOP (Medical Writer)Advisory Board: Bristol Myers Squibb, Genentech, Mirati, Pfizer, Pharmacosmos, Sanofi
Amber Lea Lambert, MSN, FNP-C, DNP (Nurse Planner)
No significant relationships to disclose.
Kam A. Newman, MD (Peer Reviewer)
No significant relationships to disclose.
Annenberg Center for Health Sciences
Staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant financial relationships to disclose.
All of the financial relationships listed for these individuals have been mitigated.
-
Aaron T. Gerds, MD, MS
Associate Professor of Medicine
Hematology & Medical Oncology
Deputy Director for Clinical Research
Cleveland Clinic Taussig Cancer Institute
Medical Director
Case Comprehensive Cancer Center Clinical Research Office
Principal Investigator
Case Lead Academic Participating Site
Cleveland, Ohio -
Michael R. Grunwald, MD
Chief, Leukemia Division
Director, Transplantation and Cellular Therapy Program
Department of Hematologic Oncology and Blood Disorders
Levine Cancer Institute
Charlotte, North Carolina
Presenting Faculty
Downloads
Learning Objectives
- Review the disease burden experienced by patients with myelofibrosis.
- Initiate treatment based on patient prognosis and characteristics.
- Implement strategies, including modifying therapy, to overcome treatment barriers.
- Describe the safety and efficacy of emerging novel therapies for myelofibrosis.
Faculty Disclosures
Aaron T. Gerds, MD, MS
Advisory Board: AbbVie, Constellation, CTI Biopharma, GSK, Imago, Kartos, Merck, MorphoSys, PharmaEssentia, Sierra Oncology
Michael R. Grunwald, MD
Consultant: AbbVie, Amgen, Astellas, Blueprint Medicines, Bristol Myers Squibb, Cardinal Health, CTI Biopharma, Daiichi Sankyo, Gamida Cell, Genentech, Gilead Sciences, GSK, Incyte Corporation, Invitae, Jazz, Ono Pharmaceutical, Novartis, Pfizer, Premier, Servier, Stemline Therapeutics
Research Support: Janssen
Stock Ownership: Medtronic